Medicare Introduce New Weight Loss Drug Including Wegovy and Zepbound
New obesity drugs are showing promising results in helping some people lose weight, but the injections remain out of reach for millions of older Americans because Medicare is prohibited from covering such drugs. A broad and growing bipartisan coalition of drugmakers and lawmakers is gearing up to push for change next year.
As obesity rates rise among older adults, some lawmakers say the United States cannot afford to maintain a decades-old law that prevents Medicare from paying for new weight-loss drugs, including Wegovy and Zepbound. Prevents from doing. But research shows that the upfront cost of covering those drugs is so high that it could deplete Medicare's already shaky bank account.
The Food and Drug Administration has in recent years approved a new class of weekly injections ...